The Third People's Hospital of Shenzhen

A clinical research and transformation platform for major emerging and re-emerging infectious diseases, leading multi-center clinical trials and real-world studies, forming an integrated closed loop of 'clinical-testing-research-public health', and providing evidence support for national infectious disease prevention and control.

Focusing on chronic viral hepatitis such as hepatitis B/C and the management of complications of liver fibrosis and cirrhosis, carrying out individualized antiviral therapy and non-invasive fibrosis assessment, and establishing a multidisciplinary consultation (MDT) channel for liver diseases.

Providing full management of HIV antiretroviral therapy (ART), drug resistance monitoring and MDT diagnosis and treatment of opportunistic infections, building a privacy-friendly follow-up and psychological support system, and carrying out clinical research on new long-acting preparations.

Targeting drug-resistant tuberculosis, complex lung infections and severe pneumonia, integrating imaging, sputum culture/molecular detection and drug sensitivity platforms to provide individualized plans and standardized isolation and hospital infection prevention and control paths.

Equipped with multiple ECMO and advanced respiratory support equipment, establishing rescue processes for ARDS, septic shock, and multiple organ dysfunction, covering transport ECMO and interdisciplinary rescue.

Based on rapid etiological diagnosis of MALDI-TOF, NGS and drug resistance gene profiles, establishing in-hospital drug resistance monitoring outposts and antimicrobial management (AMS) strategies to promote precise drug use.

Relying on BSL-3/P3 laboratories and negative pressure isolation wards, forming an emergency response capability of 'rapid screening-review-graded admission-homogeneous treatment' to support city-level public health event command.

Carrying out precise diagnosis and treatment of infectious diseases in newborns, children and pregnant women, and perinatal prevention and control strategies, standardizing mother-to-child blocking, vaccination and nutritional/immune support.

Integrating whole genome sequencing, metagenomics and single-cell technology to quickly locate pathogens, track transmission chains, and serve clinical decision-making and regional pathogen tracing.

Possessing clinical trial qualifications for drugs and medical devices, carrying out clinical research on new antiviral, anti-infection and immunomodulatory drugs, and promoting the translation of scientific research findings into clinical practice.